{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=7", "query": { "intervention": "Single intravenous doses of placebo", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 677, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T16:42:18.566Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04001647", "title": "Targeting ER Stress in Vascular Dysfunction", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Vasodilation", "Arterial Stiffness" ], "interventions": [ { "name": "Acetylcholine", "type": "DRUG" }, { "name": "Sodium Nitroprusside", "type": "DRUG" }, { "name": "Ascorbic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Colorado State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 17, "start_date": "2019-06-01", "completion_date": "2022-08-16", "has_results": false, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-10-13T16:42:18.566Z", "location_count": 1, "location_summary": "Fort Collins, Colorado", "locations": [ { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04001647" }, { "nct_id": "NCT03920293", "title": "Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Generalized Myasthenia Gravis" ], "interventions": [ { "name": "Ravulizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 175, "start_date": "2019-03-12", "completion_date": "2023-05-25", "has_results": true, "last_update_posted_date": "2024-05-28", "last_synced_at": "2026-10-13T16:42:18.566Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03920293" }, { "nct_id": "NCT02398461", "title": "An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis, Acute Relapsing" ], "interventions": [ { "name": "rHIgM22", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acorda Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 27, "start_date": "2015-04", "completion_date": "2017-09-21", "has_results": false, "last_update_posted_date": "2018-08-22", "last_synced_at": "2026-10-13T16:42:18.566Z", "location_count": 12, "location_summary": "Long Beach, California • Sacramento, California • San Francisco, California + 8 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Centennial", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02398461" }, { "nct_id": "NCT07024641", "title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis B Virus Infection" ], "interventions": [ { "name": "GIGA-2339", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GigaGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2024-11-13", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-13T16:42:18.566Z", "location_count": 12, "location_summary": "Chandler, Arizona • Huntington Beach, California • Lake Forest, California + 9 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Lake Forest", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07024641" }, { "nct_id": "NCT07305818", "title": "NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graves Disease" ], "interventions": [ { "name": "MER511 (IV)", "type": "BIOLOGICAL" }, { "name": "Placebo comparator (IV)", "type": "BIOLOGICAL" }, { "name": "MER511 (SC)", "type": "BIOLOGICAL" }, { "name": "Placebo comparator (SC)", "type": "BIOLOGICAL" }, { "name": "MER511 (SC) for MAD", "type": "BIOLOGICAL" }, { "name": "Placebo comparator (SC) for MAD", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merida Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 100, "start_date": "2025-12-19", "completion_date": "2028-07-24", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-13T16:42:18.566Z", "location_count": 11, "location_summary": "Torrance, California • Hollywood, Florida • Miami, Florida + 8 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Wesley Chapel", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07305818" }, { "nct_id": "NCT04149860", "title": "Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Alzheimer Disease" ], "interventions": [ { "name": "Lu AF87908", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 86, "start_date": "2019-09-27", "completion_date": "2023-07-19", "has_results": false, "last_update_posted_date": "2023-08-04", "last_synced_at": "2026-10-13T16:42:18.566Z", "location_count": 6, "location_summary": "Glendale, California • Hollywood, Florida • Miami, Florida + 3 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04149860" }, { "nct_id": "NCT04023994", "title": "A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimers Disease" ], "interventions": [ { "name": "RO7126209", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "MALE", "summary": "18 Years to 40 Years · Male only" }, "enrollment_count": 36, "start_date": "2019-08-03", "completion_date": "2020-07-17", "has_results": true, "last_update_posted_date": "2021-08-09", "last_synced_at": "2026-10-13T16:42:18.566Z", "location_count": 1, "location_summary": "Raleigh, North Carolina", "locations": [ { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04023994" }, { "nct_id": "NCT02127970", "title": "Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Abscess", "Wound Infection", "Surgical Site Infection", "Cellulitis" ], "interventions": [ { "name": "Dalbavancin", "type": "DRUG" }, { "name": "Dalbavancin-matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 698, "start_date": "2014-04-18", "completion_date": "2015-03-11", "has_results": true, "last_update_posted_date": "2018-09-28", "last_synced_at": "2026-10-13T16:42:18.566Z", "location_count": 25, "location_summary": "Montgomery, Alabama • Anaheim, California • Long Beach, California + 18 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Modesto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02127970" }, { "nct_id": "NCT04583969", "title": "ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Lenzilumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 527, "start_date": "2020-10-23", "completion_date": "2022-04-22", "has_results": true, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-10-13T16:42:18.566Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04583969" }, { "nct_id": "NCT03453060", "title": "Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Thrombosis" ], "interventions": [ { "name": "E-WE Thrombin- Dose 1", "type": "DRUG" }, { "name": "E-WE Thrombin- Dose 2", "type": "DRUG" }, { "name": "E-WE Thrombin- Dose 3", "type": "DRUG" }, { "name": "E-WE Thrombin- Dose 4", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Aronora, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 21, "start_date": "2018-05-30", "completion_date": "2018-11-25", "has_results": true, "last_update_posted_date": "2019-10-29", "last_synced_at": "2026-10-13T16:42:18.566Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03453060" } ] }